NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT06898957 2026-04-22
(DeLLphi-310)
Amgen
Phase 1 Active not recruiting
NCT06992609 2026-04-21
ALBORAN
AstraZeneca
Phase 3 Recruiting
NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
NCT06780137 2026-04-20
MK-6070-002
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07391670 2026-04-17
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT07005128 2026-04-16
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07531095 2026-04-15
DeLLphi-313
Amgen
Phase 1 Not yet recruiting
NCT07339059 2026-04-09
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT05903092 2026-04-07
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT03923270 2026-04-01
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT06769126 2026-03-30
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Phase 2 Recruiting
NCT07459634 2026-03-10
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT05683977 2026-02-24
ARSENAL
AstraZeneca
Active not recruiting
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT07149363 2026-02-17
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Recruiting